

# PROGRAM

*PARIS 2023*

# ImmunoRad®

**7<sup>th</sup> EDITION**  
**SEPTEMBER 27<sup>th</sup>-29<sup>th</sup>**

Registration

[www.immunorad.org](http://www.immunorad.org)

Twitter



LinkedIn



# Wednesday September 27<sup>th</sup>

13.25 - 13.30 pm Opening

## Welcome Introduction



Pr Eric Deutsch / conference co-chair

Director of Gustave Roussy Radiation Oncology Department and INSERM UMR 1030

## Primer on Cancer Immunology, Radiations and Immunotherapy




Educational Session

### 13.30-15.30 PART I


- ⌚ **13.30 -14.00** INNATE IMMUNITY  
Tumor-associated macrophages from bench to bedside,  
 Pr Alberto Mantovani, Istituto Clinico Humanitas
- ⌚ **14.00 -14.30** ADAPTIVE IMMUNITY  
Role of tertiary lymphoid structures in response to anti-cancer immunotherapy  
 Pr Antoine Italiano, Gustave Roussy
- ⌚ **14.30 -15.00** IMMUNOLOGICAL CELL DEATH  
Immunological cell death: inducers and enhancers  
 Pr Guido Kroemer, Cordeliers Research Center
- ⌚ **15.00 -15.30** ABCOPAL EFFECT  
Mechanisms of interaction of radiotherapy with immunotherapy  
 Pr Silvia Formenti, Weill Cornell Medicine

- ⌚ **15.30-16.00** Coffee break

### 16.00-18.00 PART II

- ⌚ **16.00 -16.30** CLINICAL IMMUNOTHERAPY  
How to build on the top of current chemo-radiations and PD-L1 inhibitors? The NSCLC model  
 Pr Fabrice Barlési, Gustave Roussy
- ⌚ **16.30 -17.00** DNA DAMAGE RESPONSE  
Modulating DNA damage responses to enhance radiotherapy-immunotherapy combinations  
 Pr Kevin Harrington, Institute of Cancer Research
- ⌚ **17.00 -17.30** RADIO-IMMUNOTHERAPY  
Immunogenic cell death driven by radiotherapy – Mechanisms and implications  
 Dr Lorenzo Galluzzi, Weill Cornell Medicine


### MAIN PROGRAM Keynote Presentation


- ⌚ **17.30 -18.15**  
AI for Cancer Precision Medicine  
 Pr Fabrice André, Gustave Roussy


18.00-20.00 COCKTAIL POSTER SESSION

# Thursday September 28<sup>th</sup>

## 8.30-10.00 Session I: DNA DAMAGE RESPONSE


🕒 **8.30 -9.00**  
Exploiting self-inflicted DNA breaks to evade growth limits imposed by genotoxic stress  
 **Dr Claus Sørensen**, University of Copenhagen


🕒 **9.00 -9.30**  
Chromosomal instability-induced inflammation: a catch 22 for cancer cells  
 **Dr Floris Foijer**, University of Groningen


🕒 **9.30 -10.00**  
A new role of altered R-loop homeostasis in radiation-induced tumor immunogenicity  
 **Pr Sandra Demaria**, Weill Cornell Medicine


🕒 **10.00-10.30** Coffee break

## 10.30-12.30 Session II: MYELOID CELLS

🕒 **10.30 -11.00**  
Myeloid cells in cancer  
 **Dr Mikael Pittet**, University of Geneva


🕒 **11.00 -11.30**  
Neutrophils in lung cancer: modulators of tumor growth and therapy response,  
 **Dr Etienne Meylan**, ULB


🕒 **11.30 -12.00**  
Local and abscopal responses of small-cell lung cancer to radiation therapy  
 **Pr Julien Sage**, Stanford University


🕒 **12.00 -12.30**  
Enhancing phagocytosis to magnify radiotherapy-induced in situ tumor vaccination  
 **Dr Rodney Cheng-En Hsieh**, Chang Gung Memorial Hospital


🕒 **12.30-14.00** Lunch break and exhibition

## 14.00-16.00 Session III: RT DOSE AND MODALITIES

🕒 **14.00 -14.30**  
Spatially fractionated FLASH radiotherapy modulates the antitumor immune response  
 **Dr Cristian Fernandez-Palomo**, University of Bern


🕒 **14.30 -15.00**  
Radiotherapy with carbon ions plus CTLA4 blockade elicits therapeutic immune responses in a murine tumor model  
 **Dr Stefan Eichmüller**, DKFZ Heidelberg


🕒 **15.00 -15.30**  
Revisiting the radiobiology of targeted alpha therapy  
 **Dr Jean-Pierre Pouget**, Institut de Recherche en Cancérologie de Montpellier

🕒 **15.30 -16.00**  
Radiotherapy in the context of multimodality treatment for oligometastatic disease  
 **Pr Matthias Guckenberger**, University of Zurich


🕒 **16.00-16.30** Coffee break

## 16.30-18.30 Session IV: IMMUNOSUPPRESSION

🕒 **16.30 -17.00**  
IL-1, CAFs and rectal cancer  
 **Dr Florian Greten**, Frankfurt University

🕒 **17.00 -17.30**  
Innovative approaches to trigger radiation induced immunological cell death and overcome checkpoint resistance  
 **Pr Jim Welsh**, MD Anderson Cancer Center, USA









## Keynote Presentation


🕒 **17.30 -18.15**  
Myeloid cells as a limitation of radiotherapy and radiotherapy/immunotherapy combinations- potential therapeutic strategies  
 **Pr Ralph Weichselbaum**, University of Chicago

# Friday







# September 29<sup>th</sup>

## 8.30-10.30 Session V TUMOR MICROENVIRONMENT

-  **8.30 -9.00**  
Spatial transcriptomics reveals a substantial heterogeneity in TNBC tumor and stroma compartments with potential clinical implications  
 **Pr Christos Sotiriou**, ULB
-  **9.00 -9.30**  
Immune contexture of radiation response  
 **Dr Jerome Galon**, Cordeliers Research Center
-  **9.30 -10.00**  
Reprogramming the tumour microenvironment to improve responses to radiotherapy  
 **Pr Tim Illidge**, Manchester Cancer Research Center
-  **10.00 -10.30**  
Mapping of stromal heterogeneity and plasticity in breast cancer  
 **Dr Fatima Mehta-Grigoriou**, Institut Curie





 **10.30-11.00** Coffee break

## 11.00-12.30 Session VI AI, IMAGING AND RADIOMICS

-  **11.00 -11.30**  
The role of standard imaging in radio-immunotherapy: focus on radiomics and lymphocyte sparing radiotherapy  
 **Pr Philippe Lambin**, Maastricht University
-  **11.30 -12.00**  
Predictive and prognostic role of PET in immunotherapy  
 **Dr Désirée Deandreis**, Gustave Roussy
-  **12.00 -12.30**  
Next generation radiotherapy at the era of AI and immunotherapy  
 **Pr Eric Deutsch**, Gustave Roussy

**12.30-14.00** Lunch break and exhibition

## 14.00-16.00 Session VII ADAPTIVE IMMUNITY

-  **14.00 -14.30**  
Fatty Acid metabolic regulation of anti-tumor immunity against irradiated glioblastoma  
 **Dr Claire Vanpouille-Box**, Weill Cornell Medicine
-  **14.30 -15.00**  
Human endogenous retroviruses represent a source of shared tumor epitopes for cancer immunotherapy,  
 **Pr Stephane Depil**, Centre Leon Berard

# Friday September 29<sup>th</sup>

🕒 **15.00 -15.30**  
Targeting IL2 signaling with radiotherapy to trigger systemic immunity

 **Pr Sana Karam**, University of Colorado

🕒 **15.30 -16.00**  
Impact of radiation on intestinal commensals and cancer immunosurveillance,

 **Pr Laurence Zitvogel**, Gustave Roussy


**16.00-16.30** Coffee break

## 16.30-18.30 Session VIII INNATE IMMUNITY

🕒 **16.30 -17.00**  
In situ abscopal effect: synergistic efficacy of immunotherapy and partial tumor irradiation

 **Dr Michele Mondini**, Gustave Roussy

🕒 **17.00 -17.30**  
Photon and particle radiation antitumor immune effects via senescence and NK cells

 **Pr Peter Hüber**, German Cancer Research Center

🕒 **17.30 -18.00**  
Low Dose Radiotherapy: from the lab to the clinic.

 **Dr Fernanda Herrera**, Lausanne University Hospital

🕒 **18.00 -18.30**  
Clinical and Immune correlates of response to nivolumab plus chemoradiotherapy for locally-advanced cervical cancer – NiCOL study

 **Dr Emanuela Romano**, Institut Curie